129 related articles for article (PubMed ID: 7556968)
21. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
Goldin GF; Marcinkiewicz M; Zbroch T; Bityutskiy LP; McCallum RW; Sarosiek J
Dig Dis Sci; 1997 Jul; 42(7):1362-9. PubMed ID: 9246029
[TBL] [Abstract][Full Text] [Related]
22. Esophageal mucosal resistance. A factor in esophagitis.
Goldstein JL; Schlesinger PK; Mozwecz HL; Layden TJ
Gastroenterol Clin North Am; 1990 Sep; 19(3):565-86. PubMed ID: 2228164
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of oesophageal mucosal defence.
Sarosiek J; McCallum RW
Baillieres Best Pract Res Clin Gastroenterol; 2000 Oct; 14(5):701-17. PubMed ID: 11003804
[TBL] [Abstract][Full Text] [Related]
24. Modulatory impact of acid and pepsin on esophageal hydrophobicity in humans.
DeRosa J; Marcinkiewicz M; Sarosiek J; Edmunds M; McCallum RW
Am J Gastroenterol; 1995 Nov; 90(11):2020-4. PubMed ID: 7485014
[TBL] [Abstract][Full Text] [Related]
25. Impact of acid and pepsin on human esophageal prostaglandins.
Sarosiek J; Yu Z; Namiot Z; Rourk RM; Hetzel DP; McCallum RW
Am J Gastroenterol; 1994 Apr; 89(4):588-94. PubMed ID: 8147363
[TBL] [Abstract][Full Text] [Related]
26. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat.
Sarosiek J; Feng T; McCallum RW
Am J Med Sci; 1991 Dec; 302(6):359-63. PubMed ID: 1772120
[TBL] [Abstract][Full Text] [Related]
27. Monophasic luminal release of prostaglandin E2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions. Its potential pathogenetic significance.
Marcinkiewicz M; Sarosiek J; Edmunds M; Scheurich J; Weiss P; McCallum RW
J Clin Gastroenterol; 1995 Dec; 21(4):268-74. PubMed ID: 8583097
[TBL] [Abstract][Full Text] [Related]
28. Declined human esophageal mucin secretion in patients with severe reflux esophagitis.
Namiot Z; Sarosiek J; Marcinkiewicz M; Edmunds MC; McCallum RW
Dig Dis Sci; 1994 Dec; 39(12):2523-9. PubMed ID: 7995174
[TBL] [Abstract][Full Text] [Related]
29. The effect of esophageal mechanical and chemical stimuli on salivary mucin secretion in healthy individuals.
Sarosiek J; Rourk RM; Piascik R; Namiot Z; Hetzel DP; McCallum RW
Am J Med Sci; 1994 Jul; 308(1):23-31. PubMed ID: 8010333
[TBL] [Abstract][Full Text] [Related]
30. Impact of smoking cessation on salivary function in healthy volunteers.
Trudgill NJ; Smith LF; Kershaw J; Riley SA
Scand J Gastroenterol; 1998 Jun; 33(6):568-71. PubMed ID: 9669624
[TBL] [Abstract][Full Text] [Related]
31. The esophageal mucosal barrier in health and disease: mucosal pathophysiology and protective mechanisms.
Gyawali CP; Sonu I; Becker L; Sarosiek J
Ann N Y Acad Sci; 2020 Dec; 1482(1):49-60. PubMed ID: 33128243
[TBL] [Abstract][Full Text] [Related]
32. [Ethiopathogenesis of gastroesophageal reflux disease].
Lukás K; Marecek P
Cas Lek Cesk; 2000 Aug; 139(15):455-9. PubMed ID: 22666924
[TBL] [Abstract][Full Text] [Related]
33. Evidence on secretion of epidermal growth factor by the esophageal mucosa in humans.
Sarosiek J; Hetzel DP; Yu Z; Piascik R; Li L; Rourk RM; McCallum RW
Am J Gastroenterol; 1993 Jul; 88(7):1081-7. PubMed ID: 8317410
[TBL] [Abstract][Full Text] [Related]
34. Salivary mucins in oral mucosal defense.
Slomiany BL; Murty VL; Piotrowski J; Slomiany A
Gen Pharmacol; 1996 Jul; 27(5):761-71. PubMed ID: 8842677
[TBL] [Abstract][Full Text] [Related]
35. Oesophageal defence mechanisms.
Hopwood D
Digestion; 1995; 56 Suppl 1():5-8. PubMed ID: 7556971
[TBL] [Abstract][Full Text] [Related]
36. Salivary epidermal growth factor concentration in adults with reflux laryngitis.
Eckley CA; Michelsohn N; Rizzo LV; Tadokoro CE; Costa HO
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):401-6. PubMed ID: 15467608
[TBL] [Abstract][Full Text] [Related]
37. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
Triadafilopoulos G; Kaczynska M; Iwane M
Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
[TBL] [Abstract][Full Text] [Related]
38. Salivary mucin: a factor in the lower prevalence of gastroesophageal reflux disease in African-Americans?
Rayment SA; Liu B; Offner GD; Oppenheim FG; Troxler RF
Am J Gastroenterol; 2000 Nov; 95(11):3064-70. PubMed ID: 11095319
[TBL] [Abstract][Full Text] [Related]
39. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis.
Weijenborg PW; Smout AJ; Verseijden C; van Veen HA; Verheij J; de Jonge WJ; Bredenoord AJ
Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(3):G323-9. PubMed ID: 24924748
[TBL] [Abstract][Full Text] [Related]
40. Protection and regeneration of esophageal, pharyngeal, and laryngeal mucosa as a major element in therapy of patients with esophageal and extraesophageal reflux symptoms.
Gąsiorowska A
Otolaryngol Pol; 2020 Aug; 74(4):40-45. PubMed ID: 32909960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
